Cantor Fitzgerald Comments on Atyr PHARMA FY2026 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Cantor Fitzgerald issued their FY2026 earnings per share estimates for Atyr PHARMA in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings per share of ($0.78) for the year. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Wednesday, June 4th. Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Leerink Partners began coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $18.60.

Atyr PHARMA Price Performance

Atyr PHARMA stock opened at $5.43 on Wednesday. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $483.29 million, a PE ratio of -5.78 and a beta of 0.88. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $5.98. The stock has a 50-day moving average price of $3.70 and a two-hundred day moving average price of $3.58.

Institutional Investors Weigh In On Atyr PHARMA

Institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. acquired a new stake in Atyr PHARMA during the fourth quarter worth approximately $53,093,000. Point72 Asset Management L.P. acquired a new stake in Atyr PHARMA during the fourth quarter worth approximately $17,677,000. Octagon Capital Advisors LP grew its stake in Atyr PHARMA by 294.7% during the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company’s stock worth $10,727,000 after purchasing an additional 2,652,000 shares during the period. Tikvah Management LLC acquired a new stake in Atyr PHARMA during the fourth quarter worth approximately $8,908,000. Finally, Woodline Partners LP acquired a new stake in Atyr PHARMA during the fourth quarter worth approximately $6,092,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.